NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STEGLUJAN is a fixed-dose combination tablet containing ertugliflozin (an SGLT2 inhibitor) and sitagliptin (a DPP-4 inhibitor) approved by FDA on December 19, 2017. It is indicated for type 2 diabetes management as an oral adjunctive therapy. The combination targets dual pathways: SGLT2 inhibition increases urinary glucose excretion while DPP-4 inhibition enhances incretin-mediated insulin secretion and glucagon suppression.
$0.001BPart D
Peak5.1 years to LOEProduct is at peak lifecycle stage with minimal Part D spending (~$1M in 2023), suggesting either limited market penetration or stable but modest commercial footprint requiring targeted field deployment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Started Apr 2014
1,233 enrolled
Type 2 Diabetes Mellitus
Career Relevance
STEGLUJAN currently has zero linked job openings, indicating stable team structure and limited active hiring. Career growth on this product will focus on defending market share against newer mechanisms and managing the 5.2-year runway to generic entry through payer relationships and patient outcomes programs.
Brand Manager
Worked on STEGLUJAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.